Ligand Pharmaceuticals Incorporated (LGND)

Check out top investors' recommendation for LGND
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
158.60
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company’s assets include PROMACTA, an oral thrombopoietin receptor agonist therapy for the treatment of adult patients with chronic immune thrombocytopenic purpura; Kyprolis for the treatment of multiple myeloma; AVINZA, a pain therapeutic; Viviant/Conbriza for the treatment of postmenopausal osteoporosis; Nexterone, an injectable formulation; and Viviant (bazedoxifene) for the treatment of postmenopausal osteoporosis. Its late-stage development programs comprise PROMACTA, which is in is in Phase II clinical studies for the treatment of oncology-related thrombocytopenia in patients with solid tumors, sarcoma, and Myelodysplastic Syndrome. The company’s late-stage development programs also include Merck Captisol program that is in Phase III studies; Captisol-enabled Clopidogrel, which is in Phase III studies; RE-021 program, a dual acting receptor antagonist that is in various stages of development for indications of severe kidney diseases; Dinaciclib that is in Phase IIb/III adaptive clinical trials for the treatment of patients with refractory chronic lymphocytic leukemia; and Beta-Secretase Inhibitor, which is in Phase II/III studies for treating Alzheimer's disease. In addition, its late-stage development programs comprise Captisol-enabled Delafloxacin, a Phase III clinical trial product for the management of acute seizure disorder; and Captisol-enabled Delafloxacin that is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. The company has alliances with GlaxoSmithKline, Onyx Pharmaceuticals, Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck Inc., Eli Lilly and Co., Spectrum Pharmaceuticals, and The Medicines Company. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in La Jolla, California.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Matt Hewitt Craig-Hallum Capital Buy   Nov 15, '17     170.00  Nov 15, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Nov 13, '17     158.00  Nov 13, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 18, '17     157.00  Oct 18, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Oct 11, '17     158.00  Oct 11, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 05, '17     150.00  Sep 05, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Aug 08, '17     135.00  Aug 08, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   May 22, '17     120.00  May 22, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Feb 27, '17     118.00  Feb 27, '18  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 28, '16     154.00  Oct 28, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 20, '16     151.00  Sep 20, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   Aug 14, '16     149.00  Aug 14, '17  N/A 
Joseph Pantginis Roth Capital Partners LLC Buy   May 12, '16   116.62  147.00  May 12, '17  -5.11% 
Joseph Pantginis Roth Capital Partners LLC Buy   Mar 11, '16   101.83  147.00  Mar 11, '17  7.57% 
Carol Werther Summer Street Research Buy   Mar 03, '16   97.56  146.00  Mar 03, '17  4.51% 
Joseph Pantginis Roth Capital Partners LLC Buy   Jan 04, '16   102.47  146.00  Jan 04, '17  0.03% 
Joseph Pantginis Roth Capital Partners LLC Buy   Dec 31, '15   108.42  146.00  Dec 31, '16  -6.28% 
Joseph Pantginis Roth Capital Partners LLC Buy   Nov 25, '15   104.62  144.00  Nov 25, '16  2.11% 
Joseph Pantginis Roth Capital Partners LLC Buy   Oct 23, '15   89.30  138.00  Oct 23, '16  54.54% 
Joseph Pantginis Roth Capital Partners LLC Buy   Sep 02, '15   92.42  135.00  Sep 02, '16  46.07% 
Joseph Pantginis Roth Capital Partners LLC Buy   Jul 21, '15   104.35    Jul 21, '16  29.49% 
< previous12